{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:22Z","timestamp":1792931842365,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omto.2023.100751","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:31:45Z","timestamp":1700497905000},"page":"100751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Bispecific CD33\/CD123 targeted chimeric antigen receptor T\u00a0cells for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Justin C.","family":"Boucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwas","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Vishwasrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Leick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle V.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyebb","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Spitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Guevara-Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.100751_bib1","doi-asserted-by":"crossref","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.omto.2023.100751_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omto.2023.100751_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100751_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omto.2023.100751_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2023.100751_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute graft-versus-host disease: a bench-to-bedside update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.100751_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omto.2023.100751_bib8","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Munoz","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.omto.2023.100751_bib9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in\u00a0vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2023.100751_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2023.100751_bib12","article-title":"Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omto.2023.100751_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T\u00a0cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2023.100751_bib14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2023.100751_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omto.2023.100751_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2023.100751_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2023.100751_bib18","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.omto.2023.100751_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2023.100751_bib20","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T\u00a0cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.100751_bib21","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib22","doi-asserted-by":"crossref","first-page":"106928","DOI":"10.1016\/j.leukres.2022.106928","article-title":"CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights","volume":"121","author":"Pemmaraju","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omto.2023.100751_bib23","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T\u00a0cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2023.100751_bib24","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T\u00a0cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.100751_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omto.2023.100751_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib27","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in\u00a0vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib28","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omto.2023.100751_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.omto.2023.100751_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omto.2023.100751_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T\u00a0cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2023.100751_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CJI.0000000000000306","article-title":"Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells","volume":"43","author":"Shrestha","year":"2020","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2023.100751_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-kappaB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2023.100751_bib34","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.100751_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0609.1989.tb01203.x","article-title":"Sequential expression of CD34 and CD33 antigens on myeloid colony-forming cells","volume":"42","author":"Buhring","year":"1989","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omto.2023.100751_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0002-9378(97)70155-8","article-title":"Immunophenotypic characterization of human fetal liver hematopoietic stem cells during the midtrimester of gestation","volume":"177","author":"Gilles","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.omto.2023.100751_bib38","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O'Hear","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.omto.2023.100751_bib39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2008.07153.x","article-title":"Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease","volume":"143","author":"Chevallier","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omto.2023.100751_bib40","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2023.100751_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","article-title":"Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?","volume":"104","author":"Cummins","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omto.2023.100751_bib42","doi-asserted-by":"crossref","first-page":"e0159477","DOI":"10.1371\/journal.pone.0159477","article-title":"Redirecting Specificity of T\u00a0cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors","volume":"11","author":"Thokala","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2023.100751_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100751_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2023.100751_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100751_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T\u00a0cell proliferation and lead to the amplification in\u00a0vivo of cytotoxic T\u00a0cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2023.100751_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T\u00a0cell survival through noncanonical NF-kappaB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal"},{"key":"10.1016\/j.omto.2023.100751_bib48","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2023.100751_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2023.100751_bib50","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T\u00a0cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.100751_bib51","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19 CAR-targeted T\u00a0cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2023.100751_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-6548-9_9","article-title":"Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer","volume":"1514","author":"Li","year":"2017","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:25:42Z","timestamp":1762496742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":52,"alternative-id":["S2372770523001006"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.100751","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T\u00a0cells for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.100751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100751"}}